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Chapter 1: General introduction 
1. Cerebral ischemia 
Stroke is one of the primary causes of death and long-term disability worldwide, 
followed by cardiovascular disease (Wattanapitayakul and Bauer, 2001, Pendlebury and 
Rothwell, 2009, Krishnamurthi et al., 2013). According to the World Health Organization 
(WHO), every year 15 million people suffer stroke worldwide. Out of which, more 
than 6 million die and another 5 million are permanently disabled (Rodrigo et al., 
2013). Over the last four decades, the stroke incidence in low- and middle-income 
countries has more than doubled. Moreover, stroke is a leading cause of dementia and 
depression (Owolabi et al., 2015). 
According to its clinical symptoms, stroke is classically divided into ischemic stroke 
(~85%) and hemorrhagic stroke including subarachnoid hemorrhage, due to bleedings. 
Ischemic stroke is the most common type of stroke, resulting from the blockage of 
blood vessels thereby shortage of oxygen and glucose supplied to the brain. 
Restoration of the cerebral blood flow and the supply of oxygen and glucose, the 
damage caused by ischemia should be improved. However, studies have demonstrated 
that restoring blood circulation in a short period of time can improve cerebral 
ischemic injury, which was called “effective reperfusion time”. Rapid reperfusion 
beyond the effective time aggravates ischemic injuries because of the generation of 
reactive oxygen species (ROS), produced a so-called “reperfusion injury” (Moro et al., 
2005). Both ischemia and reperfusion could result in the dysfunction of organs and 
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neuronal cell death. 
Reperfusion injury has been demonstrated by accumulating clinical and 
experimental studies. For example, the infarct size significantly increased at 6-24 h 
after reperfusion compared with permanent occlusion in a rat middle cerebral artery 
occlusion (MCAO) model (Zhang et al., 1994). Multiple pathological processes are 
involved in ischemia/reperfusion (I/R) injury, including oxidative stress, 
mitochondrial dysfunction, inflammation, blood-brain-barrier (BBB) disruption and 
so on, consequently leading to brain edema or hemorrhagic transformation (HT) and 
eventually causing neuron death and neurological dysfunctions in the brain (L et al., 
2016) (Fig.1). 
Up to date, recombinant tissue plasminogen activator (r-tPA) administration 
intravenously is the only Food and Drug Administration (FDA)-approved therapy for 
acute ischemic stroke. Originally, tPA was demonstrated to be safe within 3 h after 
stroke onset. However, recent studies have demonstrated that the therapeutic window 
of tPA treatment was extended to 4.5 h after stroke onset (Del Zoppo et al., 2009). So 
far, many investigators are doing clinical and preclinical studies about neuroprotection 
in ischemic stroke. However, few studies have been success and shown any clinical 
benefit.  
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Fig.1 Pathological signaling pathways involved in the cerebral ischemic stroke. 
Ischemic stroke causes the release of the excitatory amino acid glutamate and 
increased calcium (Ca
2+
) influx, activating numerous cellular signaling pathways. 
Reperfusion could aggregate the ischemic damage by the formation of free radical. 
ROS, as well as Ca
2+
 influx and other factors, can also permeabilize the mitochondrial 
membrane, leading to the release of proapoptotic molecules, such as cytochrome c 
into the cytoplasm. In general, apoptosis and necrosis involve in the cell death 
following cerebral ischemia/reperfusion injury. 
 
1.1 Reactive oxygen species 
Reactive oxygen species have been implicated in brain injury after cerebral 
ischemia, resulting from the imbalance of excessive production of ROS and limited 
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antioxidant defense. These oxidants, such as superoxide (O2
·−
), nitric oxide (NO·) and 
hydroxyl radical (OH
·
), can directly damage proteins, lipids, and DNA, leading to 
autophagy, apoptosis and necrosis (Love, 1999, Wong and Crack, 2008, Radermacher et al., 
2013) (Fig.2). Generally, most of the ROS are produced in mitochondria after I/R with 
increased mitochondria membrane potential (MMP). In addition, NADPH oxidase 
(NOX) could generate free radicals by transferring one electron to molecular oxygen to 
induce ROS production (Lambeth, 2004). The initial formation for ROS production is 
the conversion of the oxygen (O2) to superoxide anion (O2
·−
) consumed by 
mitochondria (Olmez and Ozyurt, 2012). O2
·−
 is a precursor of other ROS (Fig.2). 
ROS can regulate cellular growth, differentiation, proliferation and apoptosis at low 
levels (Poli et al., 2004). During cerebral reperfusion, ROS production is further 
stimulated. Unfortunately, tPA might increase ROS level and led to further damage 
(Green, 2008). 
Increased ROS are major causes of tissue damage after cerebral ischemia through 
destructing cellular proteins, lipids, and DNA, or disrupting normal cellular signaling 
and gene regulation. Elevated ROS production in mitochondria can trigger the opening 
of the mitochondrial permeability transition pore (mPTP) and further induce the release 
of cytochrome c and other apoptotic proteins into the neuronal cytoplasm, causing 
apoptotic signaling cascade after stroke (Kirkland et al., 2002). In addition, during I/R 
injury, ROS promote tissue inflammation and activates NLRP3 inflammasome 
activation (Bryant and Fitzgerald, 2009). Therapeutics such as Radicut® (MCI-186, 
edaravone), an anti-oxidative radical scavenger, have been used in the clinical setting in 
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Japan (Tanaka, 2002). However, safe and long-acting compounds for inhibiting ROS 
are needed for ischemic stroke therapy. 
 
 
Fig.2 Reactive oxygen species metabolism. ROS include free radicals, such as 
superoxide (O2
·−
), nitric oxide (NO·) and hydroxyl radical (OH
·
) and other molecular 
species, such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO
−
). O2
·−
 is 
spontaneously converted to H2O2, or catalysed by SOD (Fridovich, 1995). H2O2 can 
be fully reduced to water by GSH, or partially reduced to hydroxyl radicals (OH·) in 
the presence of reduced transition metals (Fe
2+
) (Liochev and Fridovich, 1994). In 
addition, O2
·−
 can react with NO radicals to produce peroxynitrite (ONOO
−
), a highly 
toxic molecule (Beckman and Koppenol, 1996). 
 
1.2 Blood-brain barrier dysfunction 
The BBB is a selective permeability barrier between the blood and the brain tissue, 
which mainly composed of endothelial cells, pericytes and astrocytes. BBB is 
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involved in the maintenance of central nervous system (CNS) microenvironment, 
regulation of influx and efflux transport, and protection from damage. BBB disruption 
is a common pathophysiological feature in cerebral I/R injury, and sometimes 
considered as an outcome of the processes such as oxidative stress and inflammation 
in I/R injury. NOX, which is highly expressed in the cerebrovascular endothelium, 
produces oxygen radicals during I/R, consequently leading to the loss of BBB 
integrity such as disrupting tight junctions and endothelial functions (Gursoy-Ozdemir 
et al., 2012). BBB disruption is associated with other neurodegenerative disorders 
including Alzheimer’s disease (AD) and stroke (Abraham et al., 2002, Bowman et al., 
2007). Moreover, BBB dysfunction elicits induction of proinflammatory factors, 
matrix metalloproteinases (MMP), and aquaporins (Candelario-Jalil et al., 2009, Alam 
et al., 2011), thereby resulting in cerebral hemorrhage after thrombolysis (Kanazawa et 
al., 2017). MMPs induced during I/R injury could disrupt tight junction (TJ) proteins, 
promoting the BBB leakage and entrance of neurotoxic agents to the brain (Gu et al., 
2012). TJs between adjacent endothelial cells are critical for maintenance of BBB 
structure and function by inhibiting the penetration of toxic substances into the brain 
(Mitic and Anderson, 1998).  
 
2. Protein tyrosine phosphatase 1B (PTP1B) 
Protein tyrosine phosphorylation is a key regulatory process in various cells and 
balanced by actions of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs): PTKs phosphorylate the tyrosine residues in a number of 
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proteins, while PTPs dephosphorylate tyrosine phosphorylation (He et al., 2014). 
Thus, dysregulation of protein tyrosine phosphorylation is involved in many diseases, 
such as diabetes and neurological diseases (He et al., 2014, Song et al., 
2016).  Protein tyrosine phosphatase 1B (PTP1B) is a member from PTP family and 
negatively regulates the insulin and leptin signaling pathways. In insulin signaling, 
PTP1B dephosphorylates the insulin receptors (IR) and insulin receptor substrate 
(IRS), while in leptin pathway, PTP1B dephosphorylates Janus kinase 2 (JAK2) and 
signal transducer and activator of transcription 3 (STAT3) (Tsou and Bence, 2012) 
(Fig.3).  
PTP1B expression is upregulated in the brain after LPS injection, suggesting the 
role of PTP1B in neuroinflammation (Song et al., 2016). Moreover, PTP1B levels 
increased significantly in rat spinal cord following injury (Zhu et al., 2015). PTP1B 
activation significantly promotes ER stress-induced neuronal apoptosis (Jeon et al., 
2017). PTP1B deletion in the hippocampus and cortex of mice showed significantly 
improved cognitive performance (Fuentes et al., 2012). Based on these findings, 
PTP1B may involve in brain damage and PTP1B inhibition would be a useful target 
for neurological disorders. In addition, inhibition of PTP1B could attenuate 
endothelial dysfunction (Wang et al., 2018b). In endothelial cells, PTP1B deletion 
could protect against chronic afterload-induced heart failure through improvements in 
cardiac VEGF-signaling and angiogenesis (Gogiraju et al., 2016). 
 
 8 
 
 
Fig.3 PTP1B negatively regulates insulin and leptin signaling pathways. Insulin 
stimulation is followed by IR autophosphorylation and activation, which promoting 
tyrosine phosphorylation of IRS-1, thereby activating phosphatidylinositol 3'-kinase 
(PI3K) and Akt. MAPK/ERK signaling cascade is another essential signaling pathway 
branched from IR. PTP1B could dephosphorylate IR and IRS, negatively regulates the 
insulin signal transduction. Leptin binding to leptin receptor induces the recruitment 
and tyrosine phosphorylation of JAK2, subsequently leading to STAT3-mediated 
transcription. PTP1B attenuates the leptin signal transduction through 
dephosphorylation of JAK2 and STAT3.  
 
Previously, we reported that sodium orthovanadate (Na3VO4), a PTP1B inhibitor, 
could rescue neurons from delayed neuronal death following transient forebrain 
ischemia in gerbils. This implies that nonspecific inhibition of PTP1B may be a 
potential target for stroke therapy (Kawano et al., 2001). Sodium orthovanadate can 
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activate or maintain the activity of growth factor receptors by inhibiting 
dephosphorylation of tyrosine residues, which are activated by autophosphorylation of 
tyrosine residues (Sugano et al., 2009). Furthermore, in a mouse model of tMCAO, 
treatment with sodium orthovanadate before and after arterial occlusion decreases 
ischemic damage significantly (Shioda et al., 2007). Sodium orthovanadate also 
exhibits neuroprotective effects in rat models of MCAO through activation of both Akt 
and ERK activation (Hasegawa et al., 2003). However, orthovanadate treatment by 
peripheral administration resulted in severe diarrhea because of the inhibition of 
ATPase (Shioda et al., 2007).  
 
3. KY-226 
Recently, a novel series of benzoylsulfonamide derivatives were synthesized. 
4-(biphenyl-4-ylmethylsulfanylmethyl)-N-(hexane-1-sulfonyl) benzamide (KY-226) 
was identified as a potent and selective inhibitor for PTP1B (IC50 = 0.25 µM) (Fig.4). 
KY-226 was reported to bind to the allosteric sites of PTP1B to act as a non-competitive 
inhibitor (Ki = 0.35 µM) (Morishita et al., 2017).  
 
 
Fig.4 The chemical structure of KY-226. 4-(biphenyl-4-ylmethylsulfanylmethyl)- 
N-(hexane-1-sulfonyl) benzamide 
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KY-226 exhibited high oral absorption in mice, which was enough for PTP1B 
inhibition (Morishita et al., 2017a). In db/db mice, KY-226 lowered the plasma 
glucose and triglyceride (TG) levels to exhibit anti-diabetic effects, without affecting 
body weight, possibly via improvement in insulin signaling (Ito et al., 2018). In 
high-fat diet-induced mice, anti-obesity effects of KY-226 through leptin signaling 
enhancement was demonstrated (Ito et al., 2018).   
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Chapter 2: KY-226 could protect from cerebral ischemic injury via 
AKT/eNOS and ERK signaling pathway 
1. Introduction 
In recent years, the Akt signaling pathway, which is a serine/threonine protein kinase 
with demonstrated effects on BBB dysfunction, has been an increasing focus for stroke 
researchers. Specifically, the Akt pathway has been implicated in the stabilization of 
the BBB through decreased expression of VCAM-1, ICAM-1, and β-catenin, as well as 
increased expression of claudin 3 and 5 (Radisavljevic et al., 2000, Tsoyi et al., 2010, 
Krafft et al., 2013). Akt activity is upregulated by phosphorylation at Ser573 and 
Thr308 by phosphoinositide-dependent protein 1 (PDK1) and 
phosphoinositide-dependent protein 2 (PDK2), which is downstream from 
phosphatidylinositol 3'-kinase (PI3K) (Andjelkovic et al., 1997). Several reports 
demonstrate that Akt activity decreases after I/R injury, and its reduction promotes 
I/R-induced neuronal cell death and damage (Friguls et al., 2001, Janelidze et al., 2001, 
Yano et al., 2001, Li et al., 2017).  
A number of compounds, including growth factors, estrogen, and free-radical 
scavengers have been shown to reduce ischemic damage, possibly (in part) by 
upregulating Akt phosphorylation (Zhao et al., 2006). Furthermore, activation of Akt in 
ischemic regions induces neuroprotection through regulation of eNOS (endothelial 
nitric oxide synthase) signaling. In response to various forms of cellular stimulation, 
eNOS is phosphorylated by Akt. Activation of Akt signaling by statins has also been 
shown to significantly reduce infarct size during cardiac ischemia (which was 
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completely absent in the eNOS knockout (KO) mice), suggesting that eNOS is vital to 
the protective effect of the Akt signaling cascade (Robert M. Bell, 2003). Moreover, 
studies show that neurological deficits following cerebral ischemia are more severe in 
eNOS KO mice compared with wild-type mice (Chen et al., 2005). In addition, in 2013, 
Yabuki et al. reported that supplementation with l-citrulline was able to rescue 
cerebrovascular injury by restoring eNOS expression following brain ischemia (Yabuki 
et al., 2013). Together, these findings indicate that eNOS plays a crucial role in 
Akt-mediated neuroprotection in the brain following ischemic injury. 
The p44/42 extracellular signal-regulated protein kinase (ERK) belongs to a family 
of mitogen-activated protein kinases (MAPK) (Kyriakis and Avruch, 2012), which are 
closely correlated with cerebral ischemia, like promoting neuronal survival after 
ischemia (Irving et al., 2000, Kilic et al., 2005, Zhu et al., 2013). ERK is normally 
activated in response to growth and differentiation factors, and its phosphorylation is 
increased in rodents with transient MCAO (Alessandrini et al., 1999). ERK activation 
has also been reported to be involved in increased tolerance to hippocampal ischemia 
(Choi et al., 2006), and exhibits neuroprotective effects via anti-oxidative actions 
(Wang et al., 2012). Activation of survival ERK and Akt signaling in rat brain neurons 
share a cooperative role after ischemic insults in rats (Li et al., 2003). In addition, 
erythropoietin has been shown to exert neuroprotective functions in brain hypoxia and 
ischemia by dual activation of ERK and Akt pathways (Kilic et al., 2005). 
Furthermore, ERK activation involved in the neuroprotective effects of calcitriol in rat 
models of global cerebral ischemia (Yuan et al., 2018). However, some studies have 
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found that activation of ERK can induce cell death during brain ischemia, although the 
mechanisms underlying this response remain unclear (Alessandrini et al., 1999, 
Namura et al., 2001, Zhuang and Schnellmann, 2006). In mice, treatment with U0126 
(a specific inhibitor of MEK (MAPK/ERK kinase)) has been shown to protect brain 
tissue against damage after forebrain ischemia, as well as during focal cerebral 
ischemia (Namura et al., 2001). Similarly, the MEK1 inhibitor PD98059 has been 
shown to decrease infarct volume following focal cerebral ischemia (Alessandrini et 
al., 1999). 
 
2. Results 
2.1 Pharmacokinetics of KY-226 in the blood and brain after I/R insult in vivo 
To determine if KY-226 could be useful for ischemic injury, we first determined if 
KY-266 could penetrate the BBB. To do this, we measured KY-226 concentrations in 
the plasma and brain tissues of mice after a 10 mg/kg intraperitoneal (i.p.) injection of 
KY-226 30 min following reperfusion. Results showed that KY-226 was able to enter 
the bloodstream, showing a slight increase in plasma concentrations in control mice 30 
min after injection (tmax = 0.5 ± 0.14 h; Cmax = 71.64 ± 4.41 μM) (Fig.5 A). However, the 
concentration of KY-226 in brain tissues 30 min after i.p. injection was very low, and 
almost totally gone 6 h following injection, suggesting that BBB permeability of 
KY-226 is very low (Fig.5 B). Surprisingly, KY-226 concentration in the brain 
increased significantly 30 min following injection in I/R mice compared with the sham 
group (Fig.5 B). However, in I/R mice, there was no significant difference in the 
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concentration of KY-226 between ipsilateral and contralateral brain tissues (Fig.5 C). 
Taken together, these data suggest that KY-226 can penetrate the BBB and that KY-266 
may play a specific role in cerebral ischemia. 
 
 
Fig. 5 KY-226 could enter into the brains. (A) The concentration of KY-226 in the 
blood was measured 5, 15, 30, 60, 180, 360 min after injection with 10 mg/kg KY-226 
intraperitoneally (i.p.). 
***
P < 0.001 vs 5 min after injection. n = 5. (B) Mice were 
subjected to tMCAO for 2 h and administered i.p. 10 mg/kg KY-226 30 min after 
reperfusion. The concentrations of KY226 in whole brains were measured 30 and 360 
min after injection with KY-226. 
**
P < 0.01 vs 30 min in sham group. 
*
P < 0.05 vs 360 
min in sham group. n = 6. (C) Mice were subjected to tMCAO for 2 h and 
administered i.p. 10 mg/kg KY-226 30 min after reperfusion. The concentrations of 
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KY- 226 in the contralateral and ipsilateral portions of the brains of ischemic mice were 
measured 30 and 360 min after injection with KY-226. n = 6. 
 
2.2 KY-226 exhibits a neuroprotective effect on ischemia/reperfusion in vivo 
Next, we measured the infarct volume of mice 24 h after reperfusion with TTC 
staining. Mice were treated with or without KY-226 (1, 5, 10, 30 mg/kg) by i.p. 30 min 
after reperfusion. The infarct size in vehicle-treated mice was 59.41 ± 2.83%, which 
implied success of the ischemic stroke model. As illustrated in Fig.6 A and B, 10 and 30 
mg/kg of KY-226 delivered 30 min after reperfusion significantly reduced infarct 
volume in the mice (10 mg/kg = 35.74 ± 5.26%, 30 mg/kg = 35.56 ± 5.03%) (Fig.6 A 
and B). However, lower concentrations of KY-266 (1 and 5 mg/kg) did not 
significantly reduce ischemic damage. Considering that 10 and 30 mg/kg of KY-266 
had similar effects on infarct volume, we chose 10 mg/kg as the optimum concentration 
for the following experiments.  
To further confirm the optimal timing of KY-226 treatment, we administered 10 
mg/kg KY-226 to mice at different times after reperfusion. Results found that infarct 
volume only decreased when KY-266 was administered 30 min after reperfusion (35.74 
± 5.26%), but not 1 h or 2 h (48.71 ± 8.27%, 52.29 ± 7.85%, respectively) (Fig.6 C and 
D). When compared with mice in the vehicle group, those treated with KY-226 had 
significantly decreased neurological score 24 h after reperfusion (Fig.6 E). Together, 
results suggest that KY-226 has a neuroprotective effect against I/R injury. 
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Fig.6 KY-226 reduced the ischemia/reperfusion injury in vivo. (A and B) Mice 
were subjected to tMCAO for 2 h and KY-226 with different concentrations (1, 5, 10, 
30 mg/kg) was administered intraperitoneally (i.p.) 30 min after reperfusion. 
Representative images of TTC staining (A) and quantitative analysis (B) of infarct 
volume demonstrated that 10 and 30 mg/kg KY-226 reduced the ischemic damage 
significantly 24 h after reperfusion. 
*
P < 0.05 and 
**
P < 0.01 vs Vehicle. n > 7. (C and 
D) Mice were subjected to tMCAO for 2 h and KY-226 (10mg/kg) was administered i.p. 
at 0.5, 1, 2 h after reperfusion. Representative images of TTC staining (C) and 
quantitative analysis (D) of infarct volume showed that 10 mg/kg KY-226 decreased 
the infract volume when administered 30 min after reperfusion. 
**
P < 0.01 vs Vehicle. 
n > 7. (E) Mice were subjected to tMCAO for 2 h and KY-226 (10mg/kg) was 
administered i.p. 30 min after reperfusion. The neurological deficit score in KY-226 
treatment group was significantly reduced compared with that in the vehicle group. 
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**
P < 0.01 vs Vehicle. n > 7. 
 
2.3 KY-226 activates the Akt/eNOS signaling pathway in ischemic mice 
In 2007, Shioda et al. reported that activation of the PI3K/Akt pathway mediated the 
neuroprotective effects in brain cerebral ischemia (Shioda et al., 2007). As mentioned 
previously, KY-226 has an inhibitory effect against PTP1B, which could attenuate the 
PI3K/Akt pathway. Because of this, we hypothesized that activation of Akt may be 
involved in the neuroprotective action of KY-226 following I/R insult. To test this 
hypothesis, we measured Akt activity using western blot, which was correlated with 
phosphorylation of Thr308 and Ser473 (Alessi et al., 1996). Consistent with previous 
reports (Shioda et al., 2007), levels of Akt phosphorylation in the cortex decreased 
significantly at 3 and 6 h after reperfusion, at both Ser473 and Thr308 (Fig.7 A-C). 
Meanwhile, total Akt expression did not change by ischemia/reperfusion and KY-226. 
The transient decrease in Akt phosphorylation in I/R injury model was upregulated by 
KY-226 remarkably (Fig.7 A-C). 
eNOS is one of the classic downstream targets of Akt and the Akt/eNOS signal 
transduction pathway is involved in regulating responses to I/R injury (Chien et al., 
2015). Akt could phosphorylate eNOS at Ser1177 and increase NOS activation, 
thereby leading to cardioprotection against ischemia/reperfusion (Bellis et al., 2009, 
Changjun Yang and Murugesan Velayutham, 2013). Our results showed that KY-226 
was able to restore phosphorylation of eNOS (Ser1177) 3 and 6 h after reperfusion 
without altering phosphorylation of eNOS (Thr495) or total eNOS protein expression 
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(Fig.7 D-F). NOS has three isoforms – eNOS, neuronal NOS (nNOS), and inducible 
NOS (iNOS) -- all of which participate in the regulation in response to I/R injury. 
Previous studies have suggested that nNOS may reduce I/R injury through a direct 
antioxidant effect (Khan et al., 2004, Choate et al., 2008). Results of our experiment 
showed no change in iNOS protein expression 3 and 6 h after reperfusion in both 
vehicle and KY-226-treated groups, which was associated with inflammation (Fig.7 G 
and H). However, in mice, KY-226 inhibited I/R-induced downregulation of nNOS 6 h 
after reperfusion (Fig.7 G and I). These results suggested that Akt/eNOS activation 
mediated the neuroprotection of KY-226 in cerebral ischemia in mice. 
 
 
Fig.7 KY-226 activated the Akt/eNOS signaling pathway in ischemic mice. Mice 
were subjected to tMCAO for 2 h and administered intraperitoneally (i.p.) with 10 
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mg/kg KY-226 30 min after reperfusion. (A-C) The levels of Akt and phosphorylation 
Akt with cortical samples from mice 3 and 6 h after reperfusion were measured by 
western blot analysis.
 **
P < 0.01 and 
***
P < 0.001 vs sham; 
##
P < 0.01 and 
###
P < 0.001 
vs Vehicle. n = 6. (D-F) The levels of eNOS and phosphorylation eNOS with cortical 
samples from mice 3 and 6 h after reperfusion were tested by western blot analysis. 
**
P 
< 0.01 and 
***
P < 0.001 vs sham; 
#
P < 0.05 vs Vehicle. n = 6. (G-I) The levels of iNOS 
and nNOS from ischemic brain of mice 3 and 6 h after reperfusion were measured with 
western blot analysis. 
***
P < 0.001 vs sham; 
##
P < 0.01 vs Vehicle. n = 6.  
 
2.4 KY-226 plays a vital role in ERK signaling pathway 
Studies indicate that ERK1/2 participates in a wide variety of functions in the 
mammalian brain and its activation could promote cell survival and prevent oxidative 
stress. Pervanadate, a powerful PTP1B inhibitor, has been reported to activate MAPK 
signaling (Zhao et al., 1996). To determine whether activation of ERK is involved in the 
neuroprotective effects of KY-226, we investigated the activity of ERK in mice 
subjected to I/R injury. Because the changes in the phosphorylation of ERK1 (44kD) 
and the phosphorylation ERK2 (42kD) are similar, we chose ERK2 phosphorylation to 
represent ERK activity. Consistent with previous reports (Takayuki Kawano and 
Shigetoshi Yano, 2001, Chen et al., 2017), ERK2 activity decreased significantly 
following dephosphorylation 3 and 6 h after reperfusion (Fig.8 A and B). As expected, 
10 mg/kg KY-226 was able to inhibit I/R-induced decline in the phosphorylation in 
ERK2 in mice. There was no significant difference in total ERK2 expression in mice 
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treated with or without KY-226. KY-226 itself also did not affect the expression or 
phosphorylation of Akt and ERK2 (Fig.8 C-E). The results suggested that KY-226 was 
able to activate the ERK signaling pathway in mice during cerebral ischemia. 
 
 
Fig.8 KY-226 restored the ERK activity down-regulated by ischemia/reperfusion 
damage in mice. (A and B) Mice were subjected to tMCAO for 2 h and administered 
intraperitoneally (i.p.) with 10 mg/kg KY-226 30 min after reperfusion. The levels of 
ERK and phosphorylation ERK with cortical samples from mice 3 and 6 h after 
reperfusion were measured with western blot analysis. 
**
P<0.01 and 
***
P<0.001 vs 
sham; 
#
P<0.05 and 
###
P<0.001 vs Vehicle. n = 6. (C-E) Mice were intraperitoneally 
administered with 10 mg/kg KY-226 for 3 and 6 h. The levels of proteins related to Akt 
and ERK signaling pathway in cortical samples were tested by western blot analysis. n 
= 6. 
 
 21 
 
2.5 KY-226 could attenuate the ROS stress induced by ischemia/reperfusion in 
vivo 
Oxidative damage is the most common and important event in ischemic stroke, 
which can lead to the death of nerve cells. Because of this, we assessed the effects of 
KY-226 on oxidative damage after reperfusion in mice. Results of our experiments 
showed that I/R injury significantly increased nitrotyrosine and 4-hydroxynonenal 
(4-HNE) protein expression, which peaked 12 h after reperfusion (Fig.9 A and B). 
Nitrotyrosine and 4-HNE are indicators of oxidative protein damage and lipid oxidation, 
respectively. Furthermore, 10 mg/kg of KY-226 was able to suppress the increases in 
nitrotyrosine and 4-HNE observed 12 h after reperfusion in mice subjected to I/R injury 
(Fig.9 C-E).  
Meanwhile, 12 h following reperfusion, nitrotyrosine immunofluorescence 
increased significantly. This effect was reduced by treatment with 10 mg/kg of KY-226, 
suggesting that KY-226 can block oxidative stress induced by I/R injury (Fig.10 A). 
Similar anti-oxidative effects from KY-266 treatment were observed from 4-HNE and 
8-OHdG immunohistochemistry (Fig.10 A).  
To further evaluate the neuroprotective effects of KY-226 in I/R damage, we 
co-stained nitrotyrosine and NeuN, which is a marker for neurons (Mullen et al., 1992). 
Results showed that in ischemic mice, nearly all neurons in the cortex were co-stained 
with nitrotyrosine and NeuN. In the I/R group, NeuN staining revealed reductions in the 
number of nuclei and increases in the size of nuclei, which suggested neuronal damage 
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induced by I/R (Fig.10 B). Together, these results suggest that KY-226 can attenuate 
oxidative stress in vivo following I/R injury.  
 
 
Fig.9 KY-226 could attenuate the oxidative stress induced by 
ischemia/reperfusion insult in mice. (A and B) Mice were subjected to tMCAO for 2 
h and reperfusion with different duration time. Western blot analysis of time-course of 
protein (nitrotyrosine, left) and lipid oxidation (4-HNE, right) with cortical samples 
from mice after reperfusion. (C-E) Mice were subjected to tMCAO for 2 h and 
administered intraperitoneally with 10 mg/kg KY-226 30 min after reperfusion. 
Western blot analysis of the effects of KY-226 on nitrotyrosine and 4-HNE protein with 
cortical samples from mice 12 h after reperfusion
 **
P < 0.01 and 
***
P < 0.001 vs sham; 
#
P < 0.05 and 
##
P < 0.01 vs Vehicle. n = 4.  
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Fig.10 KY-226 inhibited the ischemia/reperfusion-induced oxidative damage with 
immunohistochemistry. (A) Representative photographs of fluorescence 
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immunostaining with nitrotyrosine, 4-HNE and 8-OHdG protein. Immunoreactivity of 
nitrotyrosine, 4-HNE and 8-OHdG, which are markers of oxidative damage of protein, 
lipid and DNA (green) respectively, were stimulated in the cortex 12 h after reperfusion 
in mice. (B) Representative photographs of fluorescence immunostaining with 
nitrotyrosine (green) and NeuN (red) in the cortex 12 h after reperfusion in mice. Scale 
bar = 50 μm. Experiments were repeated for three times with similar results. 
 
3. Discussion 
In this study, a mouse model of stroke was produced by tMCAO/R. Results of this 
study showed that a potent and selective PTB1B inhibitor, KY-226, was able to enter 
the brain and diminish the volume of cerebral infarct and improve the neurological 
deficits in ischemic mice. Activation of both Akt and ERK by KY-226 in our study 
was associated with a neuroprotective action during ischemic injury. In addition, 
activation of Akt upregulated eNOS phosphorylation reduced ischemic oxidative 
stress. Together, these data suggest that KY-226 may be able to protect against 
ischemic damage following I/R injury through regulation of the Akt/eNOS and ERK 
pathways. 
PTP inhibitors induce protein tyrosine phosphorylation in intact cells. PTP1B 
inhibitors like vanadate inhibit protein tyrosine phosphatases by acting as a transition 
state of a phosphate analog, as well as by forming a reversible bond through cysteine 
residues (Morinville et al., 1998). Therefore, vanadate increases tyrosine 
phosphorylation via the inhibition of nonselective protein tyrosine phosphatases and 
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activation of tyrosine kinases in several cells (Morinville et al., 1998).  
The allosteric inhibitor KY-226, which lacks a carboxyl moiety has been 
synthesized to achieve high PTP1B selective inhibitory (Morishita et al., 2017b). 
Studies show that KY-226 functions as a non-competitive inhibitor and bounded to the 
allosteric site of PTP1B (Morishita et al., 2017b). PTP1B has also been shown to 
negatively regulate insulin signals through de-phosphorylation of insulin receptors 
and insulin receptor substrate in insulin resistance in various tissues such as liver, 
skeletal muscle, adipose tissue (Elchebly et al., 1999, Zinker et al., 2002, Wu et al., 
2005). Similarly, PTP1B has been shown to inactivate leptin signaling by 
de-phosphorylation of JAK2 and STAT3 in a hypothalamic cell line (Kaszubska et al., 
2002, Tsou and Bence, 2012). Moreover, PTP1B can be a negative regulator of CNS 
leptin and insulin signaling via direct dephosphorylation of Tub, which has been 
implicated in energy homeostasis (Prada et al., 2013). KY226 could penetrate the 
BBB and enter the brain, and protect neurons from ischemic injury. However, KY-226 
displayed low BBB permeability in the control mice.  
In the current study, oxidative stress was measured by ROS and exhibited harmful 
effects on cells. Free radicals such as O2
·-
 and OH
·
 are generated from mitochondria 
during ischemia/reperfusion, and neurons in brain are vulnerable to ROS (Li et al., 
2014). Growing evidence indicates that ROS is an initial cause of I/R injury (Venardos 
et al., 2007). There are several mechanisms that are thought to underlie ROS-induced 
neuronal damage; first, ROS can damage the proteins, lipids, nucleic acids and other 
macromolecular components in the cell (such as neurons) directly (Rahman, 2007, 
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Lochhead et al., 2010, Kalogeris et al., 2012). Second, ROS can lead to neuronal 
death via caspase-dependent and caspase-independent pathways in neurons 
(McManus et al., 2014). Finally, studies in ROS can lead to a loss of mitochondria in 
the neuron, leading to degeneration of the axon through Sarm1, an axodestructive 
factor, in primary mouse sensory neurons (Summers et al., 2014). ROS can also 
indirectly trigger the release of cytochrome c from mitochondrial membranes through 
translocation of p53, which controls the expression of genes such as Bax and Bid in 
neurons (Endo et al., 2006). In addition, Shiratori et al. found that ROS could cause 
damage to endothelial cells, causing severe disruptions in microcirculation and 
increases of hepatic ischemia (Shiratori et al., 1994).  
Activation of Akt is correlated with phosphorylation of Thr308 at its catalytic 
domain, and phosphorylation of Ser473 at the C-terminus (Alessi et al., 1996). 
Activated Akt can activate or inactivate its downstream target proteins, including Bad 
and GSK3β, by phosphorylation reactivity, thereby regulating cellular signaling in a 
variety of cells (Won et al., 2005, Koh et al., 2006). Akt phosphorylated Bad and then 
released Bcl-2 inside the mitochondria. This subsequently prevents the formation of 
the mitochondrial permeability transition pore. Bcl-2 also inhibits the secretion of 
cytochrome c into the cytosol, thereby blocking activation of executioner caspases in 
neuronal cells (Ouyang et al., 1999). Akt was inactivated in vivo by 
dephosphorylation immediately after ischemia, probably due to relative activation of 
protein phosphatases because of lack of ATP during ischemia in neurons (Ouyang et 
al., 1999). Akt activation has been shown to promote the nuclear translocation of 
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nuclear factor-erythroid 2-related factor 2 (Nrf2), which led to expression of the 
downstream protein heme oxygenase-1 (HO-1), and phosphorylation of the survival 
regulatory protein cyclic AMP-responsive element binding protein (CREB) (Zhang et 
al., 2017a, Zhang et al., 2018). Furthermore, there was no report found the negative 
effects of Akt signaling on ischemic stroke in current (Mullonkal and Toledo-Pereyra, 
2007). Akt can upregulate the Bcl-2 expression and increase the GSH and SOD 
activity to inhibit ROS generation in neurons in ischemic insult (Gao et al., 2015, 
Zhang et al., 2015, Jiao et al., 2016).  
eNOS, first identified as a substrate of Akt, could maintain cerebral blood flow 
(CBF) and reduces neuronal injury after stroke (Samdani et al., 1997). Many studies 
demonstrated that the neuroprotective effects of Akt-mediated eNOS activation 
against cerebral ischemia are due to NO production. For example, studies show that 
NO may play a role in protecting tissues against ischemia by forming intracellular 
antioxidants such as nitrosothiols and glutathione. Nitric oxide may also form 
peroxynitrite with superoxide anion during I/R injury. The formation of 
peroxynitrite is harmful to cells. However, thiol-containing agents such as 
glutathione, albumin, and cysteine agents can convert the peroxynitrite anion to 
nitrosothiols and related products, and/or decrease the release of ROS via direct 
action on a membrane component of the NADPH oxidase (Clancy et al., 1992, Fujii 
et al., 1997, Ronson et al., 1999, Guo et al., 2011). Studies also show that in mice, 
ROS production was significantly reduced when mice were treated with the eNOS 
enhancer PEx-4 (Exendin-4 -loaded poly(D,L-lactide-co-glycolide) microspheres) 
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provided the neuroprotection through p-Akt/p-eNOS pathways to attenuate oxidative 
injury in diabetic rats (Chien et al., 2015).  
The current study investigated the mechanisms underlying the protective effects of 
KY-226 in ischemic damage. Unlike Akt signaling, the question of whether activation 
of ERK exerts a protective or detrimental to neurons is still being debated, with 
differing results depending on whether growth factor-dependent neuronal survival, 
neurotoxicity induced by glutamate, oxidative stress, or ischemia is the model being 
used (Li et al., 2003). Increased phosphorylation of ERK has been noted in the 
vulnerable penumbra following the acute ischemic stroke in humans as well as in 
mouse models (Slevin et al., 2000). Activation of the ERK pathway could deliver 
survival signals and protect against spinal cord ischemia promoted by xenon 
post-conditioning in rats (Liu et al., 2016). Furthermore, ERK phosphorylation 
contributed to the inhibition of I/R induced the renal apoptosis and oxidative stress 
by hypothermia in mice (Choi et al., 2017). For example, in rats, it has been reported 
that ERK1 and 2 are present in brain mitochondria at the outer 
membrane/intermembrane space in neurons, which may help to regulate 
mitochondrial activities related to cell life and death (Alonso et al., 2004). ERK can 
also effectively inhibit ROS generation by regulating the expression of the Bcl-2 family 
in myocardial I/R injury in mice (Radak et al., 2013). For instance, in mouse brains, 
TGF-1β can activate the ERK pathway under both non-ischemic and ischemic 
conditions, which was accompanied by an increase in Bad phosphorylation (Yuan 
Zhu et al., 2002). 
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In summary, the present study demonstrated for the first time that KY-226 
penetrated the brain up to 0.55 μM (IC50 = 0.25 μM) and played a neuroprotective role 
in cerebral ischemia/reperfusion in mice. KY-226 was able to ameliorate the infarct 
size, neurological deficits, and I/R induced-ROS stress in mice. The neuroprotective 
effects of KY-226 were mediated by the activation of Akt/eNOS and ERK signaling 
pathway (Fig.11). Our study suggested that KY-226 may be a candidate for the 
treatment of ischemic stroke. It is necessary to do further studies with other ischemic 
models to evaluate the efficacy of KY-226 as a potential neuroprotective compound. 
 
Fig.11 A scheme for the proposed mechanisms for the neuroprotective effects of 
KY-226. KY-226 not only enhanced the activity of Akt and eNOS, but also restored the 
diminished ERK expression in ischemia/reperfusion insult. 
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Chapter 3: KY-226 protects blood-brain barrier function through 
Akt/FoxO1 signaling pathway in brain ischemia 
1. Introduction 
Ischemic stroke is mainly induced by a transient or permanent occlusion of blood 
vessels, resulting in neuronal death and behavioral deficits (Sommer, 2017). The 
secondary brain injury caused by I/R is in part mediated by disruption of the BBB. 
BBB leakage causes leukocyte penetration into the brain and brain edema (Fanning et 
al., 1998, Malaeb et al., 2007, Park and Lee, 2013). In this context, BBB disruption 
precedes neuronal death in brain I/R injury. 
The BBB is a dynamic interface between the blood and brain tissue to maintain the 
brain homeostasis. It consists of basement membrane, pericytes, astrocytes, and 
endothelial cells (Fig.12 A). Brain capillary endothelial cells account for 75–80% 
function in BBB (Li et al., 2010). Endothelial cells in the BBB are unique compared 
with other tissues because of the continuous intercellular TJs (Abbott et al., 2006). TJs 
are composed of occludin, claudin, junctional adhesion molecule (JAM), and 
cytoplasmic-associated proteins (Mitic and Anderson, 1998, Ballabh et al., 2004) 
(Fig.12 B). As a cytoplasmic TJ-associated protein, ZO-1 (zonula occludens-1) binds 
to occludin to recruit it into TJs (Furuse et al., 1994, Ballabh et al., 2004). Protein 
kinase C δ (PKCδ) signaling in part mediates the breakdown of TJ proteins in brain 
ischemia (Jiao et al., 2011). The activation of MMPs also mediates TJ protein 
breakdown in BBB leakage (Na et al., 2015, Wang et al., 2016). ZO-1 is 
phosphorylated under conditions of increased TJ permeability both in Madin-Darby 
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canine kidney and CVE cells, which leads to a decrease in ZO-1 and occludin levels 
(Stevenson et al., 1989, Staddon et al., 1995, Basuroy et al., 2006). The loss and 
degradation of ZO-1 are closely linked to increased barrier permeability, an effect 
related to activation of hypoxia-inducible factor-1α (HIF-1α) (Yan et al., 2012). 
 
 
Fig.12 Structure of the Blood–Brain Barrier (BBB). (A) The BBB is constituted in 
the central nervous system by capillary endothelial cells and surrounded by basement 
membrane, pericyte, astrocyte, and neurons). (B) The tight junction further is 
established by the interaction between the transmembrane proteins (claudins, occludin, 
and junction adhesion molecule (JAM)) and cytoplasmic associated-proteins (ZO-1, 
ZO-2, and ZO-3) of adjacent endothelial cells. 
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PKB/Akt signaling plays a protective role in ischemic injury by maintaining BBB 
integrity. Akt activates mTOR signaling, thereby suppressing excessive autophagy 
and Rac1 (Ras-related C3 botulinum toxin substrate 1) induction. This in turn 
preserves ZO-1 levels after oxygen-glucose deprivation and reoxygenation-induced 
damage in vitro (Wang et al., 2016, Yang et al., 2018). Extracellular signal-regulated 
kinase (ERK) is also required for epidermal growth factor (EGF)-induced prevention of 
TJ disruption induced by oxidative stress (Basuroy et al., 2006). The expression of 
active MEK1, an upstream regulator of ERK, results in enhanced junctional 
localization of ZO-1, while U0126 and dominant-negative MEK1 attenuated the 
effects of EGF in acetaldehyde-treated cells (Samak et al., 2011). 
 
2. Results 
2.1 KY-226 ameliorated BBB breakdown in brain I/R insults 
EB dye is used as a marker of albumin effluxion to evaluate BBB permeability 
(Saunders et al., 2015). As shown in Fig.13 A, I/R damaged BBB permeability. In 
contrast, treatment with KY-226 (10 and 30 mg/kg) 30 min after ischemia significantly 
diminished EB leakage compared with that of the vehicle group. The quantitative 
analysis of EB leakage after I/R is shown in Fig.13 B. These results revealed that 
KY-226 attenuated the increase in BBB permeability induced by I/R. 
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Fig.13 KY-226 ameliorated BBB breakdown in mice subjected to 
ischemia/reperfusion. (A and B) Mice were subjected to tMCAO for 2 h and 
administered with KY-226 (1, 10, 30 mg/kg, i.p.) 30 min following reperfusion. 
Representative images (A) and quantitative analysis (B) of EB leakage showed that 10 
and 30 mg/kg KY-226 decreased the EB leakage significantly 24h after reperfusion. 
*
P < 0.05 vs Vehicle. n > 8. 
 
2.2 KY-226 attenuated the degradation of TJs in the ischemic brain 
During ischemia and reperfusion, the TJs of BBB are disrupted (Fischer et al., 2002). 
Therefore, we examined the effects of KY-226 on expression of ZO-1 and occludin. 
Compared with that in the sham group, the expression of ZO-1 and occludin proteins in 
the ischemic cortex were significantly decreased in the vehicle-treated group both 12 
and 24 h after reperfusion, suggesting compromised TJs induced by I/R (Fig.14 A, C, 
and D). There was no change in CD31 protein expression, indicating endothelial cells 
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remained intact. KY-226 (10 mg/kg) administration rescued the loss of ZO-1 and 
occludin proteins 24 h after I/R insult in ischemic brains of mice (Fig.14 B, E, and F). 
We performed immunofluorescence assay for ZO-1, occludin, and CD31 proteins in 
the brain. In the cortex of sham group, ZO-1 was co-expressed with CD31. ZO-1 
immunofluorescence decreased significantly 24 h following reperfusion in ischemic 
cortex. This effect was inhibited by treatment with KY-226 (10 mg/kg), suggesting that 
KY-226 abolished the loss of ZO-1 induced by I/R injury in the brain (Fig.15 A). 
Similar results after KY-266 treatment were observed with occludin 
immunohistochemistry (Fig.15 B). Taken together, KY-226 administration appears to 
restore the decrease in ZO-1 and occludin expression in ischemic brains. 
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Fig.14 Effects of KY-226 administration on the expression of ZO-1 and occludin in 
mice treated with ischemia/reperfusion. (A) Mice were subjected to tMCAO for 2 h 
and reperfusion for 12 and 24 h. ZO-1 and occludin proteins in the brain after 
reperfusion were analyzed with western blot. (B) Mice were subjected to tMCAO for 2 
h and administered with intraperitoneally 10 mg/kg KY-226 30 min after reperfusion. 
The effects of KY-226 on the expression of ZO-1 and occludin proteins in mice 24 h 
after reperfusion were measured by western blot. (C and D) Quantitative analysis of 
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western blot results from B.
 *
P < 0.05, 
**
P < 0.01, and 
***
P < 0.001 vs sham. n = 6. (E 
and F) Quantitative analysis of western blot results from C.
 **
P < 0.01 and 
***
P < 0.001 
vs sham; 
#
P < 0.05 and 
##
P < 0.01 vs Vehicle. n = 6. 
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Fig.15 Immunohistochemistry demonstrating that KY-226 inhibited the loss of 
ZO-1 and occludin proteins in mice after ischemia/reperfusion (I/R) insults. Mice 
were subjected to tMCAO for 2 h and administered intraperitoneally with 10 mg/kg 
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KY-226 30 min after reperfusion. (A) Representative images of fluorescence 
immunostaining with CD31 (green) and ZO-1 (red) in the brain 24 h after reperfusion 
in mice. (B) Representative images of fluorescence immunostaining with CD31 (green) 
and occludin (red) in the brain 24 h after reperfusion in mice. Scale bar = 50 μm. 
Experiments were repeated for three times with similar results. 
 
2.3 KY-226 ameliorated the loss of TJ proteins via Akt signaling and ERK 
pathways 
Since KY-226 protection in brain ischemia is associated with increased Akt and ERK 
activity (Sun et al., 2018b), we next tested the effects of Akt and ERK inhibitors, 
wortmannin and U0126, respectively, to assess whether Akt and ERK modulate the 
expression of ZO-1 and occludin proteins. KY-226 treatment increased the expression 
of ZO-1 and occludin in ischemic brains 24 h after reperfusion. Wortmannin decreased 
p-Akt (Ser473) protein expression and abolished the effects of KY-226 treatment on 
ZO-1 and occludin protein expression in mice 24 h after reperfusion (Fig.16 A-C). 
Similarly, U0126 abolished the increase in ZO-1 and occludin expression induced by 
KY-226 and downregulated p-ERK protein level (Fig.16 D-F). 
To further investigate the mechanism underlying elevation of ZO-1 expression 
induced by KY-226, we measured the mRNA level of ZO-1 in mice 24 h after 
reperfusion. KY-226 significantly elevated ZO-1 mRNA level in the ipsilateral brain 
compared with that in sham and vehicle-treated groups (Fig.16 G). We treated mice 
with Akt and ERK inhibitors 30 min before ischemia. The increased ZO-1 mRNA 
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induced by KY-226 administration was blocked by Akt and ERK inhibitor treatment 24 
h after reperfusion (Fig.16 H and I). Taken together, activation of Akt and ERK appear 
to mediate the protective effects of KY-226 on TJ protein expression in cerebral 
ischemia. 
 
 
Fig.16 KY-226 ameliorated BBB dysfunction through Akt pathway and ERK 
signaling. Mice were treated with wortmannin or U0126 30 min before ischemia and 
then subjected to tMCAO for 2 h, following with treatment with KY-226 (10 mg/kg) 
intraperitoneally 30 min after reperfusion. (A-C) ZO-1, occludin, and phosphorylated 
Akt proteins in the brain 24 h after reperfusion were tested with western blot. 
***
P < 
0.001 vs sham; 
#
P < 0.05 and 
###
P < 0.001 vs Vehicle; 
&
P < 0.05 vs KY. n = 8. (D-E) 
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ZO-1, occludin, and phosphorylated ERK proteins in the brain 24 h after reperfusion 
were measured by western blot. 
***
P < 0.001 vs sham; 
#
P < 0.05 and 
##
P < 0.01 vs 
Vehicle; 
&
P < 0.05 vs KY. n = 8. (G) Quantitative RT-PCR analysis of ZO-1 mRNA in 
ipsilateral and contralateral brains from mice 24 h after reperfusion. 
*
P < 0.05 vs sham; 
#
P < 0.05 and 
##
P < 0.01 vs ipsilateral-Vehicle. n = 8. (H) Quantitative RT-PCR 
analysis of ZO-1 mRNA in the brains of mice 24 h after reperfusion. 
*
P < 0.05 vs sham; 
###
P < 0.001 vs Vehicle; 
&
P < 0.05 vs KY. n = 8. (I) The Ct value of GAPDH mRNA in 
the brains of mice 24 h after reperfusion. n = 8. 
 
2.4 KY-226 prevented LPS-induced TJ disruption in bEnd.3 cells 
To further elucidate the mechanism underlying the regulation of ZO-1 expression by 
KY-226, a brain microvascular endothelial cell model using bEnd.3 cells was used to 
investigate the effects of LPS on BBB function (Choi and Kim, 2008). ZO-1 promoter 
activity was significantly decreased after LPS treatment when cells were transfected 
with ZO-1 promoter luciferase (Li et al., 2018a). The suppression of ZO-1 promoter 
activity was abolished by KY-226 treatment (Fig.17 A and B). Similar results were 
acquired from ZO-1 immunofluorescence staining (Fig.17 C). These results implied 
that KY-226 could protect endothelial cells during inflammatory conditions. 
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Fig.17 KY-226 prevented lipopolysaccharide (LPS)-induced tight junction (TJ) 
disruption in bEnd.3 cells. bEnd.3 cells were treated with LPS (1 μg/mL) and/or 
KY-226 (1 μM) for 24 h. (A) bEnd.3 cells were transfected with ZO-1-pGL3 vector and 
the levels of luciferase reporter activity were measured 24 h after transfection. 
**
P < 
0.01 vs Con; 
##
P < 0.01 vs LPS. n = 6. (B) Western blot assay of ZO-1 and CD31 in 
bEnd.3 cells after LPS stimulation. n = 6. (C) Immunofluorescence staining of ZO-1 
(green) and DAPI (blue) in bEnd.3 cells after LPS stimulation. Scale bar = 20 μm. 
Experiments were repeated for three times with similar results. 
 
2.5 KY-226 activated Akt/FoxO1 signaling in bEnd.3 cells stimulated with LPS 
Since FoxO1 is one of the downstream targets of Akt (Nakamura et al., 2008), we 
examined the effects of LPS on Akt-FoxO1 signaling in bEnd.3 cells. As shown in Fig. 
6A, LPS stimulation reduced the phosphorylation of Akt (T308) without changing total 
Akt protein levels. The dephosphorylation of Akt (Thr308) was followed by FoxO1 
(Ser256) dephosphorylation after LPS treatment. The decreased FoxO1 
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phosphorylation (Ser256) returned to basal levels with KY-226 administration (Fig.18 
A-C). Furthermore, both wortmannin and U0126 prevented the KY-226-induced 
increase in promoter activity of ZO-1 (Fig.18 D). To further elucidate the role of FoxO1 
in the regulation of ZO-1 by KY-226, we treated cells with a FoxO1 inhibitor 
(As1842856, 10 nM). As1842856 significantly enhanced ZO-1 promoter activity after 
LPS treatment (Fig.18 E). Overexpression of FoxO1 inhibited ZO-1 promoter activity; 
this repression was ameliorated by KY-226 treatment (Fig.18 F). Collectively, these 
findings suggest that KY-226 enhanced Akt/FoxO1 signaling in bEnd.3 cells. 
 
 
Fig.18 KY-226 activated the Akt/FoxO1 signaling pathway in bEnd.3 cells 
stimulated with lipopolysaccharide (LPS). Cells were treated with LPS (1 μg/mL) 
and/or KY-226 (1 μM) for 24 h. (A-C) Western blot analysis of FoxO1, phosphorylated 
FoxO1, Akt, and phosphorylated Akt in bEnd.3 cells after LPS stimulation. 
**
P < 0.01 
and 
***
P < 0.001 vs Con;
 #
P < 0.05 and 
##
P < 0.01 vs LPS. n = 6. (D) bEnd.3 cells were 
transfected with ZO-1-pGL3 vector and treated with wortmannin (0.2 μM), U0126 (2 
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μM), or LPS (1 μg/mL) and/or KY-226 (1 μM) for 24 h. The levels of luciferase 
reporter activity were measured 24 h after transfection. 
***
P < 0.001 vs Con; 
###
P < 
0.001 vs LPS-Con; 
&&&
P < 0.001 vs LPS-KY. n = 6. (E) bEnd.3 cells were transfected 
with ZO-1-pGL3 vector and treated with LPS (1 μg/mL) and/or AS1842856 (FoxO1 
inhibitor, 10 nM) for 24 h. The levels of luciferase reporter activity were measured 24 h 
after transfection. 
***
P < 0.001 vs Con; 
##
P < 0.01 vs LPS-Con. n = 6. (F) bEnd.3 cells 
were transfected with FoxO1 plasmid and ZO-1-pGL3 vector, and treated with KY-226 
(1 μM) for 24 h. The levels of luciferase reporter activity were measured 24 h after 
ZO-1-pGL3 vector transfection. 
**
P < 0.01 vs Con; 
#
P < 0.05 vs FoxO1 OE-Con. n = 6. 
 
3. Discussion 
In this study, we reported that KY-226 rescues BBB dysfunction following cerebral 
I/R in mice. To our knowledge, this is the first study to demonstrate that both Akt and 
ERK activation by KY-226 mediates BBB protection in I/R-induced injury. We 
previously reported that Akt activation induces the phosphorylation of FoxO1 
concomitant with its translocation to the cytoplasm from the nucleus, thereby 
mediating ischemic tolerance (Fukunaga and Shioda, 2009). Sodium orthovanadate, a 
PTP inhibitor, elevated Akt activity and in turn rescued neurons from delayed neuronal 
death, where increased FoxO1 phosphorylation was associated with neuroprotection 
(Fukunaga et al., 2005). However, the downstream signaling effects of FoxO1 
phosphorylation remain unclear. 
TJs are critical for maintaining polarized barriers that exist between cerebral 
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vascular endothelial cells, which are the main structures responsible for the BBB 
permeability (Ballabh et al., 2004). Studies have demonstrated that alterations of TJ 
associated proteins contribute to the loss of BBB function in many diseases or 
disorders of CNS. Following reperfusion, ROS and cytokines could change the 
distribution and structure of TJ to increase the BBB permeability (Yang et al., 2007). 
ZO-1 is a member from the family named a membrane-associated guanylate kinase 
(MAGUK) and involved in the formation and regulation of TJs in the BBB. Occludin, 
identified by Mikio Furuse, is the first transmembrane TJ protein with high 
concentrations at BBB TJs and its precise role is unknown (Furuse et al., 1993). 
Occludin protein is not required for the formation of TJ strands and might play a role in 
strengthening TJs (Furuse et al., 1996, Hirase et al., 1997, Forster, 2008). Claudins, 
expressed in a tissue-specific manner, contain a PDZ-binding motif at the C terminus 
capable of binding to ZO-1 (Furuse et al., 1999, Itoh et al., 1999). Claudin-5 appears 
important in maintaining the BBB and is specifically important in actively regulating 
small molecule paracellular permeability. ZO-1 recognizes occludin and anchors 
transmembrane proteins to the intracellular actin cytoskeleton to stabilize TJs (Fanning 
et al., 1998). Hypoxia disrupts the localization of ZO-1 and occludin, resulting in a 
diffuse pattern with discontinuous staining at endothelial cell borders in vitro (Mark 
and Davis, 2002). The continued reduction in ZO-1 expression following cerebral 
ischemia contributes to impaired barrier function because ZO-1 is the scaffolding 
protein of occludin (Malaeb et al., 2007, Jiao et al., 2011). ZO-1 deficiency disrupts 
TJs, and reduced ZO-1 levels are associated with barrier breakdown in many 
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neurological disorders (Katsuno et al., 2008). However, the molecular mechanisms 
underlying the regulation of ZO-1 expression in vascular endothelial cells remain 
unclear. 
During CNS infections, LPS level was significantly increased, leading to increased 
permeability of brain microvascular endothelial cells, eventually resulting in cerebral 
edema (Sumi et al., 2010, Banks et al., 2015). Inflammation caused by I/R injury in the 
brain is often accompanied by BBB breakdown (Jiang et al., 2005, Amantea et al., 
2009). Thus, vascular endothelial cells are primary targets of inflammatory events 
during bacterial infections and LPS exposure (Yoneda et al., 2000). ZO-1 redistribution 
is the earliest cellular event during cell shedding and BBB breakdown (Guan et al., 
2011). For example, LPS increases the paracellular permeability of brain endothelial 
cells and decreases transendothelial electrical resistance through disruption of TJ 
proteins (Dohgu and Banks, 2008). In addition, LPS also can decrease the expression 
of claudin-5 in bEnd.3 cells (Li et al., 2018a). KY-226 could upregulate the 
expression of claudin-5 with LPS treatment in vitro (Data not shown). FoxO1 was 
reported to modulate claudin-5 expression in response to pathologic stimulations by 
binding to a repressor region in the claudin-5 promoter (Taddei et al., 2008), which 
further supporting that KY-226 could improve claudin-5 expression.  
In the present study, we focused on activation of the PI3K/Akt pathway by KY-226 
as activation of PI3K/Akt signaling mediates protection against I/R-induced damage 
and BBB disruption after ischemia. FoxO1 is a nuclear transcription factor that 
regulates the function of vascular endothelial cells (Accili and Arden, 2004, Barthel et 
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al., 2005, Greer and Brunet, 2005). Akt phosphorylates FoxO1 at three specific sites 
(Thr24, Ser256, and Ser319) in response to growth factors or insulin, thereby inducing 
translocation of FoxO1 from the nucleus to the cytoplasm (Brunet et al., 1999). 
Akt-dependent phosphorylation of FoxO1 induces formation of a complex with 14-3-3 
chaperone proteins and recruits it to the cytoplasm from the nuclear fraction (Rena et al., 
1999, Nakae et al., 2000, Rena et al., 2001). Akt depletion impairs endothelial barrier 
function and permeability (Gao et al., 2016). Increased expression of p-Akt and 
p-FoxO1 is associated with upregulation of ZO-1 and occludin in ischemic injuries in 
vivo and in vitro (Yang et al., 2016). In silico analysis using JASPAR 
(http://jaspar.genereg.net/) revealed putative association domains of FoxO1 in the 
promoter regions of ZO-1, suggesting that FoxO1 regulates ZO-1 gene expression. In 
the present study, we reported that FoxO1 regulates ZO-1 gene expression at the 
transcriptional level. Likewise, in human cerebral microvascular endothelial cells 
(hCMEC/D3), LPS treatment suppressed mRNA and protein levels of ZO-1 and 
occludin (Li et al., 2012, Qin et al., 2015). LPS-induced ZO-1 mRNA suppression was 
attenuated by KY-226 treatment. LPS binds to toll-like receptor 4 (TLR4) on the cell 
surface (Park and Lee, 2013). TLR4 activation leads to NF-κB and inflammatory 
cytokine production under LPS stimulation. In this context, NF-κB signaling may also 
underlie LPS-induced ZO-1 degradation. Further studies are required to resolve this 
question.  
Both ERK and PI3K/Akt pathways synergistically mediate FoxO1 transcriptional 
activity in vitro (Sun et al., 2018a). PI3K and ERK inhibitors (LY294002 and U0126) 
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inhibited FoxO1 phosphorylation, indicating that the PI3K and ERK pathways 
regulated FoxO1 by phosphorylation rather than by changing FoxO1 expression levels 
(Wang et al., 2018a). Our results suggest that both signaling pathways are required for 
the induction of ZO-1 by KY-226. However, further studies are required to fully 
characterize FoxO1 regulation by ERK signaling after I/R injury. 
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Chapter 4: Summary 
1. Conclusions 
1) We first detected the pharmacokinetics of KY-266 in mice exposed to brain 
cerebral ischemia. We demonstrated that KY-226 could enter the bloodstream with 
a slight increase in the plasma concentration. Moreover, KY-226 was able to 
penetrate the BBB after ischemia/reperfusion injury. 
2) KY-226, a novel PTP1B inhibitor, exhibited a neuroprotective effect in a 
dose-dependent manner in mice brain cerebral ischemia model. 
3) I also measured the ROS levels after cerebral ischemia/reperfusion insults in mice 
and evaluated the effects of KY-226 on the oxidative stress. Western blotting and 
immunohistochemistry analysis showed that KY-226 could significantly 
ameliorate the oxidative damage induced by ischemia/reperfusion injury. 
4) In mice, the transient decreased activity in Akt and eNOS proteins induced by 
cerebral ischemia was upregulated by KY-226 administration. Moreover, KY-226 
activated ERK activity following ischemia/reperfusion insults in mice. The 
activation of Akt/eNOS signaling and improvement of ERK activity were 
contribute to the neuroprotective effects of KY-226 in cerebral 
ischemia/reperfusion. 
5) Because of the low permeability of KY-226 in control mice, I also detected the 
effect of KY-226 on the BBB function following ischemia/reperfusion. KY-226 
was able to protect from BBB dysfunction in mice cerebral ischemia/reperfusion 
injury. Both Akt and ERK activation by KY-226 mediates BBB protection in 
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I/R-induced injury. 
6) In vitro study, LPS treatment caused TJs disruption in bEnd.3 cells. KY-226 
enhanced ZO-1 promoter activity after LPS treatment in cultured endothelial cells. 
KY-226 treatment prevented LPS-induced TJs disruption in cultured endothelial 
cells. 
7) Finally, KY-226 upregulated FoxO1 phosphorylation after LPS treatment in 
cultured endothelial cells. KY-226 protects BBB integrity by restoration of TJ 
proteins, an effect partly mediated by Akt/FoxO1 pathway activation.  
8) KY-226 may be a potential neuroprotective candidate for ischemic stroke and 
other neuroinflammatory diseases (Fig.19). 
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Fig.19 A scheme for the proposed mechanisms underlying the protective effects of 
KY-226 on the blood-brain barrier (BBB) in ischemia/reperfusion (I/R) or 
lipopolysaccharide (LPS) stimulation. (A) In pathological conditions such as I/R 
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and/or LPS stimulation, phosphorylation of Akt is suppressed. The inactivation of Akt 
prevents the phosphorylation of FoxO1 and its translocation into the cytoplasm. FoxO1 
accumulation in the nucleus may interact with the DNA binding domain in the promoter 
of ZO-1 and repress its transcription. This may result in the loss of ZO-1 in tight 
junctions, disrupt endothelial barrier function, and increase BBB permeability. (B) 
KY-226 increases the phosphorylation of Akt in ischemic conditions and after LPS 
treatment. Phosphorylation of FoxO1, dependent on Akt activation (p-Akt), prevents 
FoxO1 localization in the nucleus, consequently leading to the transcription of ZO-1. 
 
2. Future prospect 
In present study, we suggest that the novel PTP1B inhibitor, KY-226, has a 
protective role in neurodegenerative disease-stroke. Compared with sodium 
orthovanadate and VO(OPT), both were non-selective PTP1B inhibitors, the half-life 
(t(1/2)) of clearance of KY-226 was determined to be longer, about 1.4 h in the plasma 
(for orthovanadate and VO(OPT): 5 min and 15 min, respectively) (Shioda et al., 
2007). In addition, orthovanadate treatment by peripheral administration caused 
severe diarrhea. Up to now, 10 and 30 mg/kg KY-226 treatment orally did not elicit 
any toxicity in mice (Ito et al., 2018). From the pharmacokinetics of KY-266, we 
showed that KY-226 was difficult to penetrate the BBB in control mice with low 
permeability. Nevertheless, KY-226 was present in the brain after I/R injury in mice 
with i.p. administration. In the future, we could moderate the structure of KY-226 to 
achieve other compounds with high permeability across BBB and neuroprotective 
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effects against I/R injury. 
In Japan, edaravone (Radicut®), a free radical scavenger, is used to treat acute 
ischemia stroke (AIS) patient within 24 h of the attack (Lapchak, 2010a). Edaravone 
could suppress free radicals and inhibit vascular endothelial injuries, thereby 
protecting the neurovascular unit (Watanabe et al., 1988). 3 mg/kg edaravone 
treatment immediately after reperfusion decreased cortical infarction in rat focal 
ischemia model (Watanabe et al., 1994). In the rabbit small clot embolic stroke model 
(RSCEM), possibly an effective translational tool to gauge the clinical potential of 
new treatments, edaravone administration subcutaneously could decrease behavioral 
deficits when up to 3 hours post-embolization (Lapchak and Zivin, 2009). For tPA, a 
therapeutic window of 1–1.5 h in the RSCEM and 3–4.5 h in AIS patients, the 
therapeutic window ratio is approximately 3 (Lapchak, 2010b). In this research, 10 
mg/kg KY-226 was demonstrated to protect mice from brain ischemia within 30 min 
after reperfusion. It is of great interest to detect the dosing and timing relationship in 
clinical trials for stroke therapy.  
As we known, tPA is the only one FDA-approved drug for stroke, but the short 
therapeutic window and side effects, especially HT, limit the clinical use. Therefore, it 
has been proposed to combine tPA with other agents as a useful strategy to overcome 
the limitations of tPA. In current, tPA and edaravone were established therapies to 
recanalize an occluded artery in clinical practice. However, there are still many 
patients who do not achieve recanalization. Moreover, tPA treatment was reported to 
disrupt the BBB and induce edama and HT after stroke (Wang et al., 2004). KY-226 
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was exhibited antioxidant effects like edaravone and protected BBB function in brain 
ischemia. Based on these observations, we could consider the combination therapy of 
tPA and KY-226 for stroke treatment. We suppose that KY-226 may inhibit the 
activation of MMP-9 and block the tPA-induced ROS or trap the ROS derived from 
I/R injury. In addition, KY-226 may ameliorate edema in the ischemic brain when 
combined with tPA. In conclusion, KY-226 may attenuate delayed tPA-induced 
complications in preclinical stroke models via ROS inhibition and BBB protection. 
However, further studies are needed to explore this possibility and whether the 
combination of KY-226 and tPA could extend the therapeutic window of tPA. 
Imatinib, a tyrosine kinase inhibitor, can block the signalling of platelet-derived 
growth factor alpha (PDGF-α) receptors and was used to treat with the chronic 
myelogenous leukemia (CML) and other cancers. Imatinib could reduce the HT 
induced by delayed tPA treatment at the dose of 200 mg/kg orally administered 1 h 
after onset of ischemia in mice (Su et al., 2008). Compared to KY-226, a high dose of 
imatinib (200 mg/kg) is required to attenuate the side effects of tPA. KY-226 was 
demonstrated to have neuroprotective effects against ischemia at the dose of 10 mg/kg. 
Furthermore, 10 and 30 mg/kg KY-226 treatment orally did not elicit any toxicity in 
mice (Ito et al., 2018). Severe toxicities of imatinib such as low blood counts, nausea 
and vomiting, have been reported (Uzer et al., 2013). Nevertheless, considering that 
the studies of this paper are preclinical studies, we need do much more researches to 
confirm the protective effects of KY-226 on cerebral ischemia in the future. 
LPS has been widely used as an inflammation inducer in many experimental 
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studies and to cause neuroinflammation and neurodegeneration because LPS could 
enhance the release of proinflammatory mediators, such as cytokines (Block et al., 
2007). Although LPS models cannot precisely mimic the conditions in 
neurodegenerative disease in human, many studies demonstrated that LPS is 
neurotoxic. LPS is known to disrupt the BBB and alter many other aspects of BBB 
function and many diseases, such as multiple sclerosis, AD and stroke, are associated 
with both inflammation and BBB disruption (Xaio et al., 2001, Abraham et al., 2002). 
In human umbilical vein endothelial cells, LPS could exacerbate inflammation 
responses by inducing ROS overproduction (Zhang et al., 2017b). LPS also causes 
transmigration of leukocytes thereby exacerbating brain inflammation. Infections are 
common events following stroke and are often associated with worse outcome. 
Therefore, the detrimental effects of LPS on stroke outcome are clinically relevant. 
Thus, control of inflammation is considered to be an important strategy for the 
treatment of BBB dysfunction. Nevertheless, we showed that KY-226 could block the 
BBB disruption induced by LPS in bEnd.3 cell. We expected that KY-226 could be 
used in the clinical therapy in the future.  
Alzheimer's disease is a chronic neurological disorder, which characterized by 
memory loss and dementia. During AD, Aβ oligomers could stimulate removal of IRs 
from the membranes of neurons and inactivate insulin signaling (Zhao et al., 2008, 
Ma et al., 2009). Insulin signaling in the brain is known to decline with age and could 
prevent the pathogenic binding of Aβ oligomers (De Felice et al., 2009). Moreover, 
alteration of microvascular permeability and disruption of the BBB are noted in AD 
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besides ischemic stroke. Based on these backgrounds, KY-226, an allosteric PTP1B 
inhibitor with anti-diabetic effects through enhancements in insulin signaling in db/db 
mice, may be the potential therapeutic treatment for Alzheimer's disease. 
In conclusion, the novel PTP1B inhibitor, KY-226, maintained BBB integrity in 
ischemic stroke and LPS-induced inflammation. KY-226 may be a potential 
neuroprotective candidate for ischemic stroke and other neuroinflammatory diseases. 
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Materials and Methods 
Materials 
The following primary antibodies were purchased from Cell Signaling Technology 
(USA): phospho-Akt (Ser-473) antibody, phospho-Akt (Thr-308) antibody, Akt 
antibody, phosphor-eNOS (Ser-1177) antibody, phospho-eNOS (Thr-495) antibody, 
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody, p44/42 MAPK (Erk1/2) 
antibody, phospho-FoxO1 (Ser-256) antibody, and FoxO1 antibody. ZO-1 and occludin 
antibodies were purchased from ThermoFisher (Japan). Mouse anti-eNOS antibody, 
mouse anti-nNOS antibody and rat anti-CD31 antibody were purchased from BD 
Biosciences (San Diego, CA, USA). Anti-iNOS antibody, anti-nitrotyrosine antibody, 
anti-NeuN antibody and FoxO1 inhibitor As1842856 were purchased from Merck 
Millipore (Darmstadt, Germany). 4-HNE antibody was purchased from JaICA (Japan 
Institute for the Control of Aging, Shizuoka, Japan). β-tubulin and β-Actin were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Wortmannin was purchased 
from Sigma-Aldrich. U0126 was purchased from Promega (Madison, WI, USA). Other 
chemicals used in this study were purchased from Wako (FUJIFILM Wako Pure 
Chemical Corporation, Osaka, Japan). 
 
Cell lines and culture 
Mouse brain microvascular endothelial cells (bEnd.3) were grown in Dulbecco's 
modified Eagle's medium (DMEM, Wako) supplemented with 10% fetal bovine serum 
(FBS, Gibco, CA, USA) and 1% penicillin-streptomycin (Yang et al., 2017). Cell 
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culture was performed in a humidified atmosphere of 5% CO2/95% air at 37°C in the 
incubator. After reaching 80-90% confluence, the cells were passaged in trypsin 
(0.25%)-EDTA (0.02%)-containing PBS at a split ratio of 1:5. The media were changed 
every 2 days (Ma et al., 2013). 
 
Animals 
Adult male ICR mice, weighing 25-30 g, were purchased from Clea Japan, Inc. 
(Tokyo, Japan). Animals were housed under conditions of constant temperature and 
humidity, kept on a 12: 12-h light: dark cycle (lights on 9–21 h), and fed ad libitum. 
All procedures for handling animals complied with the Guide for Care and Use of 
Laboratory Animals and were approved by the Animal Experimentation Committee of 
Tohoku University Graduate School of Pharmaceutical Sciences. 
 
Transmit middle cerebral artery occlusion (tMCAO) and reperfusion in mice 
Mice were randomly assigned to sham, tMCAO and tMCAO + KY-226 groups. The 
tMCAO model in mice was performed as previously described (Clark et al., 1997). 
Briefly, adult male ICR mice were anesthetized using a combination anesthetic (M/M/B: 
0.3/4/5) i.p., which was prepared with 0.3 mg/kg of medetomidine (Domitol, Meiji 
Seika Pharma Co., Ltd., Tokyo, Japan), 4.0 mg/kg of midazolam (Dormicum, Astellas 
Pharma Inc., Tokyo, Japan), and 5.0 mg/kg of butorphanol (Vetorphale, Meiji Seika 
Pharma Co., Ltd.) (Kawai et al., 2011). Then the tMCAO surgical procedure was 
performed as follows: a 6-0 suture (Doccol Corporation, USA) coated with silicone was 
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inserted from the right external carotid artery to the internal carotid artery, until 
occluded the origin of the middle cerebral artery. After 2 h, the suture was carefully 
withdrawn for reperfusion. Mice in the sham operation group underwent the same 
procedure except for suture insertion. Mice were kept in a warming blanket after 
surgery. 
 
Drug administration and Experimental design in vivo  
KY-226 was procured from Kyoto Pharmaceutical Industries, Ltd. (Kyoto, Japan). 
During in vivo studies, KY-226 (1-30 mg/kg) was dissolved in 10% 
1-methyl-2-pyrrolidinone, 5% mixed solution (Cremaphor EL with ethanol 1:1) and 
ddH2O. KY-226 was freshly prepared prior to use and injected at 10 mg/kg 
intraperitoneally 30 min after reperfusion. Vehicle mice were injected with the same 
solution and same volume without KY-226 (Fig.20). 
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Fig.20 Illustration of the protocols for treatment, including the time line of the 
experiments and measurement in ischemia/reperfusion in mice. ICR mice were 
subjected to tMCAO for 2 h. (A) For dose-course experiments, different concentrations 
of KY-226 (1, 5, 10, 30 mg/kg) were administered intraperitoneally (i.p.) to mice 30 
min after reperfusion. For time-course experiments, 10 mg/kg KY-226 was 
administered i.p. at 0.5, 1, and 2 h after reperfusion. TTC staining was performed at 24 
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h after reperfusion. (B) 10 mg/kg KY-226 was administered i.p. to mice 30 min after 
reperfusion. Proteins associated with Akt/eNOS and ERK signaling pathways were 
measured 3 and 6 h after reperfusion with western blot. (C) 10 mg/kg KY-226 was 
administered i.p. to mice 30 min after reperfusion. Oxidative stress levels were 
measured 12 h after reperfusion with western blot and immunostaining. (D) For the 
wortmannin group, 50 μM wortmannin was injected into the right lateral ventricle 
(0.4 mm anterior to bregma, 0.8 mm lateral to bregma, 2.5 mm deep, 2 μl/injection 
site) 30 min before ischemia. For the U0126 group, the mice were treated with 0.5 
mg/kg U0126 via the tail vein 30 min before ischemia. Thereafter, KY-226 10 mg/kg 
was intraperitoneally administered to mice 30 min after reperfusion. Samples were 
prepared 24 h after reperfusion for further experiments, such as Evans Blue leakage, 
western blot, immunofluorescence, and RT-PCR. 
 
Measurement of KY-226 concentration in the blood and brain 
Mice were administrated 10 mg/kg of KY-226 by i.p., directly or 30 min after 
reperfusion. At 5, 15, 30, 60, 180, 360 min following injection, blood as collected from 
the tail vein for further experiments. At 30 and 360 min after injection, mice were 
anesthetized and perfused with ice-cooled PBS to remove blood. Brain samples were 
then procured from mice and stored at –80 °C until use. Plasma samples (10 μl) were 
deproteinized by adding 250 µL of acetonitrile containing phenytoin (4 ng/mL) as an 
internal standard (IS) followed by vortex and sonication. Samples were centrifuged at 
16,500 g for 20 min at 4 °C. After centrifugation, supernatant was evaporated to 
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dryness using a centrifugal concentrator (CC-105, TOMY, Tokyo, Japan), and then the 
residue was dissolved in 20 µl of 20% acetonitrile. For brain sample preparation, 500 µl 
of acetonitrile was added to a 2 ml tube containing brain hemispheres (140-220 mg). 
The mixture was then homogenized with BEADS CRUSHER (µT-12, TAITEC, 
Saitama, Japan) at 3200 rpm for 30 sec. Then, the samples were centrifuged at 16500 g 
for 20 min at 4 °C. The 10μl of supernatant was processed using the same procedure as 
plasma samples. 
Using ultra performance liquid chromatography (Ultimate 3000, Dionex), the 
chromatographic separation was performed on ACQUITY UPLC® BEH Phenyl 
column (2.1 × 50 mm, 1.7 μm, Waters, Milford, MA, USA) maintained at 40 °C at a 
flow rate of 300 µl/min (0-0.5 min, 2.5-3.0 min) and 400 µl/min (0.5-2.5 min). The 
mobile phase was composed of water (A) and acetonitrile (B) with a gradient program 
(0-0.5 min 20% B; 0.5-2.1 min 90% B; 2.1-2.5 min 100% B; 2.5-3.0 20% B). An 
injection volume with 5 µl was applied for analysis. 
Mass spectrometry was performed using a TSQ Vantage mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA) with the electrospray ionization (ESI) interface. 
Quantitative analysis was performed using selected reaction monitoring (SRM) mode 
(KY-226; m/z [M - H]
-
 480.2 > 312.1, phenytoin; m/z [M - H]
-
 251.1 > 208.1). 
 
Infarct volume evaluation 
After 24 h of reperfusion, mice were killed by decapitation and brains were rapidly 
removed and cooled to -30 °C for 10 min. Brains were cut into five sections (2 mm 
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thick) and incubated in 1% 2, 3, 5-triphenyltetrazolium chloride (TTC, Wako, Japan) 
for 20 min at 42 °C and then fixed in 4% paraformaldehyde (PFA; Sigma, USA). The 
white represents the infarct area, whereas the non-infarcted region will appear red. 
Infarct volume was measured using ImageJ software and expressed as a percentage of 
total hemisphere (Clark et al., 1997). 
 
Neurological score 
24 h after reperfusion, a neurological deficit grading system with a scale of 0 to 4 
was carried out to evaluate neuronal function impairment after ischemic stroke as 
described previously (Longa et al., 1989). The following scale rating was used: 0, No 
neurological deficit; 1, failure to extend left forepaw completely, a mild focal 
neurological deficit; 2, circling to the left, a moderate focal neurological deficit; 3, 
falling to the left, an sever focal neurological deficit; 4, not walking spontaneously and 
decreasing level of consciousness; 5. death. If the animal score was 0 or 5, it was 
removed from the study. The mice in the sham group exhibited no manifestations of 
neurological deficits (Arumugam et al., 2007).  
 
Assessment of cerebral blood flow 
The regional cerebral blood flow (rCBF) of mice was monitored by laser-Doppler 
flowmetry (FLO-C1, OMEGAWAVE, Tokyo, Japan) (Murozono et al., 2004). A guide 
cannula was perpendicularly implanted into the right cortex (2 mm posterior and 5 
mm lateral to the bregma). The probe was inserted through the guide cannula into the 
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cortex. The baseline values were recorded 5 min before ischemia and rCBF during 
ischemia was expressed as a percentage of the baseline values. When these is an 
approximately 80-90% reduction in CBF, it is considered a success model. Regarding 
rCBF and body weight of mice, there were no significant differences between the 
Vehicle and KY-226-treated group (Table 1). 
 
Evans Blue leakage 
Evans Blue (EB) leakage is used to assess BBB permeability (Li et al., 2018b). In 
brief, 18 h after reperfusion, the mice were injected with 2% EB (4 mL/kg) via the tail 
vein. 6 h later, mice were perfused with phosphate buffered saline (PBS) until the 
perfusate turned clear. Brains were rapidly removed for imaging. Brains were cut into 
four sections (2 mm thick) and scanned. For quantification of EB leakage, the right 
brains were collected and homogenized with 50% trichloroacetic acid (TCA) solution. 
Samples were incubated overnight at room temperature and then centrifuged for 30 min 
at 1000 g at 4°C. EB in the supernatants of each sample were subsequently measured at 
620 nm with a microplate reader (Flexstation 3, Molecular Devices, San Jose, USA). 
 
Western blotting 
Following decapitation, brain samples were procured from mice at the indicated 
time following reperfusion and stored at –80 °C. Frozen samples were homogenized in 
800 μl buffer containing 50 mM Tris–HCl, pH 7.4, 0.5% Triton X-100, 4 mM EGTA, 
10 mM EDTA, 1 mM Na3VO4, 40 mM Na2P2O7·10H2O, 50 mM NaF, 100 nM 
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calyculin A, 50 μg/ml leupeptin, 25 μg/ml pepstatin A, 50 μg /ml trypsin inhibitor, and 
1 mM dithiothreitol. Samples were then centrifuged at 12000 rpm for 10 min at 4 °C to 
remove insoluble material. Protein concentration was determined using Bradford’s 
assay, and samples were boiled for 5 min at 100 °C with 6X Laemmli’s sample buffer 
(Yabuki and Fukunaga, 2013).  
For electrophoresis, equal amounts of protein were loaded on 10-12% SDS–
polyacrylamide gels and transferred to a polyvinylidene diflouride membrane for 2 h 
(Towbin et al., 1979). After blocking with TTBS solution (50 mM Tris–HCl, pH 7.5, 
150 mM NaCl, and 0.1% Tween 20) containing 5% fat-free milk powder for 1 h at 
room temperature, membranes were incubated with primary antibodies overnight at 
4 °C. After washing, membranes were incubated with the appropriate secondary 
antibodies diluted in TTBS solution for 2 h at room temperature. The membranes were 
developed using an enhanced chemiluminescence (ECL) immunoblotting detection 
system (Amersham Biosciences, NJ, USA) and visualized on X-ray film (Fuji Film, 
Tokyo, Japan). 
Immunofluorescence staining 
For immunohistochemical analyses, mice were transcardially perfused with ice-cold 
phosphate buffered saline (PBS, pH 7.4), followed with 4% paraformaldehyde in 0.1M 
sodium phosphate buffer (pH7.4) immediately. Brains were removed and fixed in 4% 
PFA overnight at 4 °C. Brain samples were cut into 50 μm coronal sections using a 
vibratome (Dosaka EM Co. Ltd., Kyoto, Japan). Sections were washed in PBS for 20 
min, permeabilized with 0.1% Triton X-100 in PBS for 2 h, and blocked in PBS 
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containing 1% BSA and 0.3% Triton X-100 for 1 h at room temperature or 4 °C 
overnight (Yabuki and Fukunaga, 2013). Next, brain samples were incubated with 
specific primary antibodies in blocking solution for 3 d at 4 °C as following: mouse 
anti-nitrotyrosine, mouse anti-4-HNE, mouse anti-8-OHdG, mouse anti-NeuN, rabbit 
anti-ZO-1, mouse anti-occludin, and rat anti-CD31. After being rinsed with PBS, the 
sections were incubated with appropriate secondary antibodies (Alexa Fluor 
conjugated, Invitrogen, CA, USA) overnight at 4°C. After several washes in PBS, brain 
sections were mounted on slides with Vectashield (Vector Laboratories, Inc., 
Burlingame, CA, USA). Immunofluorescent images were analyzed using a confocal 
laser scanning microscope (Nikon, Tokyo, Japan). 
The bEnd.3 cells were grown on coverslips in 24-well plates and treated with 
lipopolysaccharide (LPS) (1 μg/mL, Sigma-Aldrich) and KY-226 (1 μM) for 24 h. Then, 
the cells were rinsed with PBS and fixed with 4% PFA for 15 min followed by 
permeabilization for 30 min. After blocking with 3% BSA for 1 h, the cells were 
incubated with primary antibody against ZO-1 (1:50) at 4°C overnight. After rinsing, 
cells were incubated with secondary antibody for 2 h at room temperature. The nuclei 
were stained with DAPI (0.5 μg/mL, Vector Laboratories, Burlingame, CA) for 5 min.  
 
Real-time quantitative polymerase chain reaction (RT-PCR)  
Total RNA was extracted from brains with TRIzol reagent (Invitrogen, USA) and 
used in reverse transcription as described previously (Shinoda et al., 2016). Real-time 
PCR amplification was performed using iQ CYBR Green Supermix (Bio-Rad 
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Laboratories, Redmond, WA, USA) following the manufacturer’s protocol. The 
amount of ZO-1 mRNA was determined using the comparative threshold (Ct) method 
by normalizing the ZO-1 mRNA Ct values to those for GAPDH (ΔCt). Statistical 
analysis of real-time PCR data was performed using 2
-ΔΔCt
 values (Livak and 
Schmittgen, 2001). The primer sequences used in this study were as follows:  
Mouse Tjp1 (ZO-1) forward: 5′- GAAATACCTGACGGTGCTGC-3′ 
Mouse Tjp1 (ZO-1) reverse: 5′- TGGAGTTACCCACAGCTTCC-3′ 
Mouse Gapdh forward: 5′- TGACGTGCCGCCTGGAGAAA-3′ 
Mouse Gapdh reverse: 5′- AGTGTAGCCCAAGATGCCCTTCAG-3′ 
 
ZO-1 luciferase reporter assay 
Mouse genomic DNA was used to amplify the ZO-1 promoter fragment (positions 
-3025/+83) and subcloned into pGL3-Basic-luciferase vector (Promega) (Lei et al., 
2010). All cloned DNA fragments were confirmed by DNA sequencing. bEnd.3 cells in 
3.5 cm dishes were transfected with 2 μg of ZO-1-pGL3 vector, as well as 100 ng of 
renilla luciferase plasmid. The cells were stimulated 6 h later with LPS (1 μg/mL) and 
KY-226 (1 μM) for 24 h. Thereafter, cells were washed with PBS and lysed with 
passive lysis buffer (1×PLB). Luciferase and renilla activities were measured with the 
dual-luciferase reporter assay kit (Promega) using a luminometer (Gene Light 55, 
Microtec, Funabashi, Japan). Relative luciferase activity was expressed as the ratio of 
firefly luciferase activity to renilla luciferase activity (Chen et al., 2008). 
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Statistical analysis 
Data were presented as mean ± S.E.M and were evaluated with One-Way Analysis 
of Variance (ANOVA) followed by Tukey’s post hoc test using the GraphPad Prism 
(GraphPad Software, Inc., La Jolla, CA, USA). A difference was considered 
statistically significant when P < 0.05. 
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Table 1. Physical parameters of mice treated with or without KY-226 (10 mg/kg) 
before and after ischemia/reperfusion. 
Parameters Vehicle KY-226 
rCBF (%) 
  
before ischemia 100 100 
after ischemia 18.07 ± 1.72 17.06 ± 1.18 
Weight (g) 
  
before ischemia 32.32 ± 0.58 32.17 ± 0.42 
after reperfusion 27.16 ± 0.54 27.05 ± 0.61 
Values are mean ± s.s.m. rCBF was monitored from 5 min before ischemia to 
reperfusion. n = 7. The weights of mice were measured at 20 min before ischemia and 
24 h after reperfusion. n = 10. There were no significant differences between the 
Vehicle and KY-226-treated group. 
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